Alvion Pharmaceuticals Announces Strategic Investment by iGrow Venture Partners
Alvion Pharmaceuticals S.M.S.A. is pleased to announce a strategic investment by iGrow Venture Partners VC, marking an important milestone in the company’s continued growth and international expansion.
This collaboration reflects a shared vision to advance innovation in the pharmaceutical sector, with a focus on the development of high-value generics and value-added, IP-driven medicines across key therapeutic areas.
This milestone comes at a time of strong momentum for Alvion, as the company continues to expand its product portfolio and strengthen its international presence.
Through this partnership, Alvion aims to further strengthen its research and development capabilities, accelerate product development timelines, and expand its global footprint across regulated and emerging markets.
iGrow Venture Partners brings significant experience in supporting high-growth companies, offering not only capital but also strategic guidance, international network access, and expertise in scaling innovative businesses.
Alvion Pharmaceuticals has established a strong track record in developing differentiated pharmaceutical products through a flexible and scalable operating model, combining scientific excellence, regulatory expertise, and strategic partnerships worldwide.
This collaboration represents a further step toward Alvion’s long-term ambition of becoming a vertically integrated pharmaceutical company, while continuing to deliver value to partners, healthcare systems, and patients globally.
Commenting on the anouncment, John Bouros, CEO of Alvion, stated:
“We are delighted to welcome iGrow Venture Partners alongside Alvion at this important stage of our journey. Their strategic perspective and experience in scaling innovative businesses align strongly with our vision. Together, we aim to accelerate our growth, strengthen our R&D platform, and expand our global reach.”
About Alvion Pharmaceuticals
Alvion Pharmaceuticals is a Greece-based pharmaceutical company with a strong international orientation, focused on the development of generics and value-added, IP-driven medicines. The company operates through a flexible, partnership-driven model and is committed to delivering highquality, accessible treatments across global markets.
About iGrow Venture Partners
iGrow Venture Partners is a growth venture capital fund focused on supporting innovative companies with strong international potential. The fund combines financial investment with strategic support, enabling portfolio companies to scale and expand across global markets.
For any related enquiries, please contact:
Ms. Marina Ioannidou at communications@alvionpharma.com
